Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Mahmoud Abu-Amna"'
Autor:
Jair Bar, Raya Leibowitz, Niels Reinmuth, Astrid Ammendola, Eyal Jacob, Mor Moskovitz, Adva Levy-Barda, Michal Lotem, Rivka Katsenelson, Abed Agbarya, Mahmoud Abu-Amna, Maya Gottfried, Tatiana Harkovsky, Ido Wolf, Ella Tepper, Gil Loewenthal, Ben Yellin, Yehuda Brody, Nili Dahan, Maya Yanko, Coren Lahav, Michal Harel, Shani Raveh Shoval, Yehonatan Elon, Itamar Sela, Adam P. Dicker, Yuval Shaked
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionImmune checkpoint inhibitors have made a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). However, clinical response varies widely and robust predictive biomarkers for patient stratification are lacking. Here, we cha
Externí odkaz:
https://doaj.org/article/926af04f4d0440e18244af89ddf7f699
Autor:
Jarushka Naidoo, Igor Puzanov, Jair Bar, Niels Reinmuth, Alona Zer, Michal Harel, Adam Dicker, Michal Lotem, Anirban Chatterjee, Mahmoud Abu-Amna, Mor Moskovitz, Adam Hassani, Itamar Sela, Yehonatan Elon, Iris Kamer, Adva Levy-Barda, Abed Agbarya, Ina Koch, David Farrugia, Gillian Price, Tatiana Harkovsky, Rivka Katzenelson, Ben Yelin, Raya Leibowitz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/0e3e42ead80141f4b5b96a3923da8e1d
Autor:
Miri Cohen, Yosi Shamay, Johanna Czamanski-Cohen, Katerina Shulman, Shoshana Keren Rosenberg, Mahmoud Abu-Amna, Ilit Turgeman, Ludmila Merkin Livshits, Revital Birenboim, Monica Dines, Gil Bar-Sela
Publikováno v:
Cells, Vol 12, Iss 20, p 2471 (2023)
Substantial evidence has accumulated showing that psychological distress affects immune regulation, the response to cancer treatment, and survival. The effect of psychological parameters on the effectiveness of immune checkpoint inhibitor (ICI) treat
Externí odkaz:
https://doaj.org/article/716e0e3ef40244f088c1ade32faa8ad1
Autor:
Antoni Ribas, Inge Marie Svane, Paolo Antonio Ascierto, Victoria Atkinson, Razi Ghori, Anna Maria Di Giacomo, Georgina V Long, Henrik Schmidt, Jacob Schachter, Eduard Gasal, Paola Queirolo, Michal Lotem, Michele Del Vecchio, Pier Francesco Ferrucci, Rosalie Stephens, Mahmoud Abu-Amna, Scott J Diede, Elizabeth S Croydon
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance. Mature results on
Externí odkaz:
https://doaj.org/article/06d6c0dbe8904dc09538e628a3bd82da
Autor:
Joshua Aviram, Gil M. Lewitus, Yelena Vysotski, Mahmoud Abu Amna, Anton Ouryvaev, Shiri Procaccia, Idan Cohen, Anca Leibovici, Luiza Akria, Dimitry Goncharov, Neomi Mativ, Avia Kauffman, Ayelet Shai, Gil Bar-Sela, David Meiri
Publikováno v:
Frontiers in Pain Research, Vol 3 (2022)
The use of medical cannabis (MC) to treat cancer-related symptoms is rising. However, there is a lack of long-term trials to assess the benefits and safety of MC treatment in this population. In this work, we followed up prospectively and longitudina
Externí odkaz:
https://doaj.org/article/0e62212239e74aa79ad8acd7045b712e
Autor:
Petros Christopoulos, Michal Harel, Coren Lahav, Itamar Sela, Nili Dahan, Niels Reinmuth, Ina Koch, Alona Zer, Mor Moskovitz, Adva Levy-Barda, Michal Lotem, Hovav Nechushtan, Rivka Katzenelson, Abed Agbarya, Mahmoud Abu-Amna, Maya Gottfried, Ella Tepper, Christine B. Ambrosone, Ido Wolf, Yanyan Lou, Raya Leibowitz, Adam P. Dicker, David P. Carbone, David Gandara
ImportanceAdvanced stage non-small cell lung cancer (NSCLC) patients with no driver mutations are typically treated with immune checkpoint inhibitor (ICI)-based therapy, either in the form of monotherapy or concurrently with chemotherapy, while treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae81768a379fb89e842974009b951303
https://doi.org/10.1101/2022.12.01.22282769
https://doi.org/10.1101/2022.12.01.22282769
Autor:
Michal Harel, Coren Lahav, Ido Wolf, Ella Tepper, Maya Gottfried, Raya Leibowitz, Mahmoud Abu-Amna, Abed Agbarya, Rivka Katzenelson, Michal Lotem, Mor Moskovitz, Alona Zer, Ina Koch, Niels Reinmuth, Adam Dicker, David Gandara, Petros Christopoulos, David Carbone
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ddb7ee0308478271dcd31c0bab19cf9
https://doi.org/10.1136/jitc-2022-sitc2022.0136
https://doi.org/10.1136/jitc-2022-sitc2022.0136
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Michal Harel, Petros Christopoulos, Coren Lahav, Itamar Sela, Nili Dahan, Niels Reinmuth, Ina Koch, Alona Zer, Mor Moskovitz, Adva Levy-Barda, Michal Lotem, Hovav Nechushtan, Rivka Katzenelson, Abed Agbarya, Mahmoud Abu-Amna, Maya Gottfried, Ido Wolf, Ella Tepper, Yanyan Lou, Raya Leibowitz, Adam P. Dicker, David Gandara, David P. Carbone
Publikováno v:
Cancer Research. 83:2159-2159
Introduction: Treatment modality selection for metastatic NSCLC patients (immunotherapy alone vs. combination of immunotherapy with chemotherapy) relies mainly on determining the programmed cell death 1 (PD-L1) expression levels in the tumor. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a5bb145575cf4c0f99987d80f4dfe67
https://doi.org/10.1158/1538-7445.am2023-2159
https://doi.org/10.1158/1538-7445.am2023-2159